Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: A case report

Abstract

Highlights This is the first report regarding the perioperative management of patients with concurrent multiple myeloma and malignant solid tumor. Our case highlights the need to devise a perioperative management strategy for multiple myeloma patients. Surgeons should be familiar with the risks associated with discontinuation of multiple myeloma drugs. Continuation of the multiple myeloma agent may be preferable in patients who do not have marked myelosuppression.

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report

“…Zuo et al reported that first-line therapy with bortezomib and the maintenance use of lenalidomide after lung tumor resection complicated by MM could have helped achieve a satisfactory therapeutic effect for > 3 years without progression despite relapse after the first year [ 1 ]. By contrast, Ujiie et al presented a case with concurrent MM and gastric cancer with rapid liver metastasis progression and subsequent death post gastrectomy and lenalidomide discontinuation [ 24 ]. They believed that lenalidomide discontinuation promoted tumor angiogenesis and lowered antitumor immunity.…”